CMV: FDA approves Livtencity for treating post-transplant infections

The U.S. Food and Drug Administration approved Livtencity (maribavir) as the first drug for treating adults and pediatric patients (12 years of age and older and weighing at least 35 kilograms) with post-transplant cytomegalovirus (CMV) infection/disease that does not respond (with or without genetic mutations that cause resistance) to available antiviral treatment for CMV. Livtencity [...]

The post CMV: FDA approves Livtencity for treating post-transplant infections appeared first on Outbreak News Today.